Влияние секса на нормальное функционирование предстательной железы

1. Сомов А.Н., Суслин С.А. Рак предстательной железы. Эпидемиология, факторы риска и раннее выявление. Профилактическая медицина. 2020;23(3):149-55 [Somov AN, Suslin SA. Prostate cancer. Epidemiology, risk factors and early detection. Profilakticheskaya meditsina. 2020;23(3):149-55 (in Russian)]. DOI:10.17116/profmed202023031149
2. Rider JR, Wilson KM, Sinnott JA, et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016;70(6):974-82. DOI:10.1016/j.eururo.2016.03.027
3. Имшинецкая Л.П. Сексология и андрология. Киев, 1997 [Imshinetskaia LP. Seksologiia i andrologiia. Kiev, 1997 (in Russian)]. 
4. Тюзиков И.А. Клинико-экспериментальные параллели в патогенезе заболеваний предстательной железы. Современные проблемы науки и образования. 2012;1:114. Режим доступа: www. science-education.ru/101-5476. Ссылка активна на 01.03.2023 [Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;1:114. Available at: www. science-education.ru/101-5476. Accessed: 01.03.2023 (in Russian)].
5. Nankin HR, Calkins JH. Pituitary-gonadal function during sleep in healthy aging men. Clin Endocr Metab. 1986;63:14.
6. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocr. 1981;4:49-61. DOI:10.1111/j.1365-2265.1981.tb00364.x
7. Udry JR, Billy JO, Morris NM, et al. Serum androgenic hormones motivate sexual behavior in adolescent boys. Fertil Steril. 1985;43(1):90-4.
8. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990;70(3):792-7. DOI:10.1210/jcem-70-3-792
9. Тюзиков И.А., Мартов А.Г., Греков Е.А. Взаимосвязь компонентов метаболического синдрома и гормональных нарушений в патогенезе заболеваний предстательной железы (обзор литературы). Экспериментальная и клиническая урология. 2012;3:39-46 [Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;3:39-46 (in Russian)].
10. Csikós E, Horváth A, Ács K, et al. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. 2021;26(23):7141. DOI:10.3390/molecules26237141
11. Oelke M, Bachmann A, Descazeaud A. Guideline on the Management of Male Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obsruction (BPO). 2012;74.
12. El-Alfy M, Luu-The V, Huang XF, et al. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 1999;140(3):1481-91. DOI:10.1210/endo.140.3.6585
13. Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am. 1999;83(5):1213-29. DOI:10.1016/s0025-7125(05)70159-0
14. Park II, Zhang Q, Liu V, et al. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology. 2009;150(10):4594-605. DOI:10.1210/en.2008-1591 
15. Kester RR, Mooppan UM, Gousse AE, et al. Pharmacological characterization of isolated human prostate [published correction appears in J Urol. 2003 Dec;170(6 Pt 1):2394]. J Urol. 2003;170(3):1032-8. DOI:10.1097/01.ju.0000080440.74266.b1
16. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96(9):1339-54. DOI:10.1111/j.1464-410X.2005.05831.x
17. Del Bello F, Bonifazi A, Giorgioni G, et al. Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells. Eur J Med Chem. 2019;168:461-73. DOI:10.1016/j.ejmech.2019.02.056
18. Franklin RB, Juang HH, Zou J, Costello LC. Regulation of citrate metabolism by androgen in human prostate carcinoma cells. Endocrine. 1995;3(8)603-7.
19. Costello LC, Liu Y, Zou J, Franklin RB. Mitochondrial aconitase gene expression is regulated by testosterone and prolactin in prostate epithelial cells. Prostate. 2000;42(3):196-202. DOI:10.1002/(sici)1097-0045(20000215)42:3<196::aid-pros5>3.0.co;2-8
20. Zhang J, Zhang M, Tang J, et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24(1):49-57. DOI:10.1038/s41391-020-00277-1
21. Silva RS, Lombardi APG, de Souza DS, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N-cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. Int J Biochem Cell Biol. 2018;96:40-50. DOI:10.1016/j.biocel.2018.01.008
22. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci. 2006;1089:1-13. DOI:10.1196/annals.1386.009
23. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-83. DOI:10.1111/j.1743-6109.2010.01991.x
24. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12(4):157-80.
25. Lee SN, Kraska J, Papargiris M, et al. Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. Sci Rep. 2021;11(1):6352. DOI:10.1038/s41598-021-85439-4
26. Corona G, Jannini EA, Mannucci E, et al. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med. 2008;5(8):1991-8.
DOI:10.1111/j.1743-6109.2008.00803.x 
27. Godoy A, Montecinos VP, Gray DR, et al. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab. 2011;300(2):E263-75. DOI:10.1152/ajpendo.00210.2010
28. Kozlowski R, Kershen RT, Siroky MB, et al. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol. 2001;165(3):1019-26.
29. Uckert S, Kuczyk MA. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract. Handb Exp Pharmacol. 2011;202:527-42. DOI:10.1007/978-3-642-16499-6_23
30. Comar VA, Petersen CG, Mauri AL, et al. Influence of the abstinence period on human sperm quality: analysis of 2,458 semen samples. JBRA Assist Reprod. 2017;21(4):306-12. DOI:10.5935/1518-0557.20170052
31. Apostolopoulos V, Bojarska J, Chai TT, et al. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021;26(2):430. DOI:10.3390/molecules26020430
32. Akbarian M, Khani A, Eghbalpour S, Uversky VN. Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action. Int J Mol Sci. 2022;23(3):1445. DOI:10.3390/ijms23031445
33. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-8. DOI:10.1016/j.drudis.2014.10.003
34. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26:2700-7. DOI:10.1016/j.bmc.2017.06.052
35. Сельков С.А., Петленко С.В., Селькова М.С. Применение препарата простатилен в комплексной терапии хронического простатита, ассоциированного с половыми и репродуктивными нарушениями. Андрология и генитальная хирургия. 2012;3:97-100 [Selkov SA, Petlenko SV, Selkova MS. Use of prostatilene in the combination therapy of chronic prostatitis associated with sexual and reproductive disorders. Andrology and Genital Surgery. 2012;3:97-100 (in Russian)].
36. Ткачук В.Н., Альшукри С., Лоцтан-Медведев А.К. Наш опыт применения витапроста у больных хроническим простатитом. Нефрология. 2005;9(4):84-8 [Tkachuk VN, Al-Shukri A, Lotstan-Medvedev AK. Оur experiences with application of vitaprost in chronic prostatitis patients. Nephrology (Saint-Petersburg). 2005;9(4):84-8 (in Russian)]. DOI:10.24884/1561-6274-2005-9-4-84-88
37. Давидов М.И. Сексуальная дисфункция у больных хроническим простатитом и ее коррекция. Урология. 2020;1:51-8 [Davidov MI. Sexual dysfunction in patients with chronic prostatitis and its correction. Urology. 2020;1:51-8 (in Russian)]. DOI:10.18565/urology.2020.1.51-58 

________________________________________________

1. Somov AN, Suslin SA. Prostate cancer. Epidemiology, risk factors and early detection. Profilakticheskaya meditsina. 2020;23(3):149-55 (in Russian). DOI:10.17116/profmed202023031149
2. Rider JR, Wilson KM, Sinnott JA, et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016;70(6):974-82. DOI:10.1016/j.eururo.2016.03.027
3. Imshinetskaia LP. Seksologiia i andrologiia. Kiev, 1997 (in Russian). 
4. Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;1:114. Available at: www. science-education.ru/101-5476. Accessed: 01.03.2023 (in Russian).
5. Nankin HR, Calkins JH. Pituitary-gonadal function during sleep in healthy aging men. Clin Endocr Metab. 1986;63:14.
6. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocr. 1981;4:49-61. DOI:10.1111/j.1365-2265.1981.tb00364.x
7. Udry JR, Billy JO, Morris NM, et al. Serum androgenic hormones motivate sexual behavior in adolescent boys. Fertil Steril. 1985;43(1):90-4.
8. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab. 1990;70(3):792-7. DOI:10.1210/jcem-70-3-792
9. Tyuzikov IA. Clinical and experimental parallels in the pathogenesis of prostate diseases. Modern Problems of Science and Education. 2012;3:39-46 (in Russian).
10. Csikós E, Horváth A, Ács K, et al. Treatment of Benign Prostatic Hyperplasia by Natural Drugs. Molecules. 2021;26(23):7141. DOI:10.3390/molecules26237141
11. Oelke M, Bachmann A, Descazeaud A. Guideline on the Management of Male Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obsruction (BPO). 2012;74.
12. El-Alfy M, Luu-The V, Huang XF, et al. Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology. 1999;140(3):1481-91. DOI:10.1210/endo.140.3.6585
13. Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am. 1999;83(5):1213-29. DOI:10.1016/s0025-7125(05)70159-0
14. Park II, Zhang Q, Liu V, et al. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasia-derived prostate stromal cells. Endocrinology. 2009;150(10):4594-605. DOI:10.1210/en.2008-1591 
15. Kester RR, Mooppan UM, Gousse AE, et al. Pharmacological characterization of isolated human prostate [published correction appears in J Urol. 2003 Dec;170(6 Pt 1):2394]. J Urol. 2003;170(3):1032-8. DOI:10.1097/01.ju.0000080440.74266.b1
16. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countries. BJU Int. 2005;96(9):1339-54. DOI:10.1111/j.1464-410X.2005.05831.x
17. Del Bello F, Bonifazi A, Giorgioni G, et al. Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells. Eur J Med Chem. 2019;168:461-73. DOI:10.1016/j.ejmech.2019.02.056
18. Franklin RB, Juang HH, Zou J, Costello LC. Regulation of citrate metabolism by androgen in human prostate carcinoma cells. Endocrine. 1995;3(8)603-7.
19. Costello LC, Liu Y, Zou J, Franklin RB. Mitochondrial aconitase gene expression is regulated by testosterone and prolactin in prostate epithelial cells. Prostate. 2000;42(3):196-202. DOI:10.1002/(sici)1097-0045(20000215)42:3<196::aid-pros5>3.0.co;2-8
20. Zhang J, Zhang M, Tang J, et al. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24(1):49-57. DOI:10.1038/s41391-020-00277-1
21. Silva RS, Lombardi APG, de Souza DS, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N-cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. Int J Biochem Cell Biol. 2018;96:40-50. DOI:10.1016/j.biocel.2018.01.008
22. Prins GS, Huang L, Birch L, Pu Y. The role of estrogens in normal and abnormal development of the prostate gland. Ann N Y Acad Sci. 2006;1089:1-13. DOI:10.1196/annals.1386.009
23. Corona G, Monami M, Rastrelli G, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272-83. DOI:10.1111/j.1743-6109.2010.01991.x
24. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev Urol. 2010;12(4):157-80.
25. Lee SN, Kraska J, Papargiris M, et al. Oxytocin receptor antagonists as a novel pharmacological agent for reducing smooth muscle tone in the human prostate. Sci Rep. 2021;11(1):6352. DOI:10.1038/s41598-021-85439-4
26. Corona G, Jannini EA, Mannucci E, et al. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med. 2008;5(8):1991-8.
DOI:10.1111/j.1743-6109.2008.00803.x 
27. Godoy A, Montecinos VP, Gray DR, et al. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. Am J Physiol Endocrinol Metab. 2011;300(2):E263-75. DOI:10.1152/ajpendo.00210.2010
28. Kozlowski R, Kershen RT, Siroky MB, et al. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol. 2001;165(3):1019-26.
29. Uckert S, Kuczyk MA. Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract. Handb Exp Pharmacol. 2011;202:527-42. DOI:10.1007/978-3-642-16499-6_23
30. Comar VA, Petersen CG, Mauri AL, et al. Influence of the abstinence period on human sperm quality: analysis of 2,458 semen samples. JBRA Assist Reprod. 2017;21(4):306-12. DOI:10.5935/1518-0557.20170052
31. Apostolopoulos V, Bojarska J, Chai TT, et al. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021;26(2):430. DOI:10.3390/molecules26020430
32. Akbarian M, Khani A, Eghbalpour S, Uversky VN. Bioactive Peptides: Synthesis, Sources, Applications, and Proposed Mechanisms of Action. Int J Mol Sci. 2022;23(3):1445. DOI:10.3390/ijms23031445
33. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-8. DOI:10.1016/j.drudis.2014.10.003
34. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26:2700-7. DOI:10.1016/j.bmc.2017.06.052
35. Selkov SA, Petlenko SV, Selkova MS. Use of prostatilene in the combination therapy of chronic prostatitis associated with sexual and reproductive disorders. Andrology and Genital Surgery. 2012;3:97-100 (in Russian).
36. Tkachuk VN, Al-Shukri A, Lotstan-Medvedev AK. Оur experiences with application of vitaprost in chronic prostatitis patients. Nephrology (Saint-Petersburg). 2005;9(4):84-8 (in Russian). DOI:10.24884/1561-6274-2005-9-4-84-88
37. Davidov MI. Sexual dysfunction in patients with chronic prostatitis and its correction. Urology. 2020;1:51-8 (in Russian). DOI:10.18565/urology.2020.1.51-58 

А.В. Ершов*1,2, Е.Н. Саверская3

1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2 ФГБНУ «Федеральный научно-клинический центр реаниматологии и реабилитологии», Москва, Россия; 
3 ФГБОУ ВО «Российский биотехнологический университет (РОСБИОТЕХ)», Москва, Россия
*salavatprof@mail.ru

________________________________________________

Anton V. Ershov*1,2, Elena N. Saverskaya3

1 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2 Federal Scientific and Clinical Center for Resuscitation and Rehabilitology, Moscow, Russia;
3 Russian Biotechnological University (ROSBIOTECH), Moscow, Russia
*salavatprof@mail.ru